Innovation Pharmaceuticals (OTCQB:IPIX) a clinical stage biopharmaceutical company, is pleased to report the Company has signed a drug supply contract with Evonik Corporation, a world leader in specialty chemicals, for the bulk production of commercial-grade Brilacidin to prepare for, as well as expedite, its continued clinical development.
As quoted in the
vTv Therapeutics, Teligent, EyePoint Pharmaceuticals, Catalyst Biosciences and Eleven Biotherapeutics were last week’s top gainers.
In case you missed it, here is this week’s cannabis big news roundup.
Kalytera Therapeutics, Inc. (TSXV:KALY, OTCQB:KALTF) (the “Company” or “Kalytera”) today announced that the Company has elected to issue 772,346 common shares of the Company (“Common Shares”) to The Salzman Group in payment of the most recent invoice issued under the services agreement with The Salzman Group previously announced on December
Abeona Therapeutics (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products has granted Orphan Drug Designation (EMA/OD/013/18) for Abeona’s gene therapy program ABO-202 for the treatment of
The cell-therapy company’s share price increased by over 90 percent after the milestone announcement was released on Thursday.
CTD Holdings (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that the company has finalized a cooperative research agreement with Kerwin Research Center, LLC to explore the use of cyclodextrins in the treatment of Alzheimer’s disease.
By Pia Rivera
Kalytera Therapeutics, Inc. (TSXV:KALY. OTCQB:KALTF) announced that the U.S. Patent and Trademark Office (“USPTO”) issued U.S. Patent No. 9,889,100 B2 with claims covering the use of cannabidiol (“CBD”) for the treatment of severe and refractory graft versus host disease.
Medigus and HC Marbella International Hospital announced the first successful MUSE procedure for GERD treatment on a single patient in Spain.
Mesoblast (Nasdaq:MESO) (ASX:MSB) today provided an update on the Phase 3 and Phase 2b clinical trials of the Company’s proprietary allogeneic mesenchymal precursor cell (MPC) product candidate MPC-150-IM in patients with moderate-to-severe and end-stage advanced chronic heart failure (CHF), respectively. These indications represent major unmet medical needs due to the
Biomerica (Nasdaq:BMRA) today reported net sales of $4,433,785 for the nine months ending February 28, 2018, compared to $4,342,247 for the period ended February 28, 2017. Sales for the three months ending February 28, 2018 were $1,375,666 compared to $1,499,930 for the period ended February 28, 2017.
As quoted in the
Aptevo Therapeutics (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced the presentation of new data for APVO436, a bispecific antibody candidate targeting CD123 and CD3, at the American Association for Cancer Research (AACR) 2018 Annual Meeting. The preclinical data demonstrate potent T-cell cytotoxicity of tumors
Idera Pharmaceuticals (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel oligonucleotide therapeutics for oncology and rare diseases, today announced it has entered into a clinical development support agreement with Pillar Partners Foundation. Under the terms of the agreement Pillar Partners will provide direct funding
Apricus Biosciences (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the outcome of its end-of-review meeting with the U.S. Food and Drug Administration (FDA) on the New Drug Application (NDA) for Vitaros™ (alprostadil, DDAIP.HCl), a topical cream for the treatment of erectile dysfunction.
As quoted in the
Novelion Therapeutics, EyePoint Pharmaceuticals, CytRx, Viking Therapeutics and AVEO Pharmaceuticals were last week’s top gainers.
EyeGate Pharmaceuticals (NASDAQ:EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, announced today the pricing of a public offering of an aggregate of 35,156,250 shares of common stock (or common stock equivalents) and warrants to purchase an aggregate of 35,156,250